SEATTLE & INDIANAPOLIS--(BUSINESS WIRE)--Cyrus Biotechnology has signed a software licensing agreement with Indiana University Research and Technology Corporation (IURTC) at Indiana University (IU) to commercialize the SparksX software package developed at the lab of former IU professor Yaoqi Zhou at the Indianapolis campus.
Cyrus (cyrusbio.com) offers a highly automated protein structure prediction and design software-as-a-service (SaaS) package, “Cyrus Bench,” for both bench scientists and computational biologists/chemists.
SparksX, combined with Rosetta from David Baker’s lab at the University of Washington (UW) and licensed to Cyrus, leads the competition in protein homology modeling, both in the biennial CASP and weekly CAMEO “blinded” competitions.
SparksX, developed by Zhou and his team, recognizes protein folds and identifies “deep” (difficult to detect) protein sequence similarity, or homology, better than any other software package, winning first place in CASP 6.
The Cyrus founding team brings decades of protein modeling and high-performance computing experience, with UW Professor David Baker, scientific advisor, Lucas Nivon, CEO, Yifan Song, CSO, Javier Castellanos, CTO.
“As a powerful tool for molecular modeling, SparksX is positioned to help further establish Cyrus as a leader in the drug development space. They have a suite of products that were originally developed through academic work across multiple universities, and Cyrus is a fine example of how startup ventures can further the impact of such research and translate these developments into the marketplace. We are delighted to partner with the Cyrus team to bring the SparksX software to market,” said Marie Kerbeshian, VP of Technology Commercialization at IURTC.
IURTC is a not-for-profit agency that helps IU faculty and researchers realize the commercial potential of their discoveries, accounting for more than 2,800 inventions and more than 80 startup companies.
About Cyrus Biotechnology, Inc.
Cyrus delivers a powerful and easy-to-use molecular modeling and design tool to disrupt the existing market for molecular modeling in BioPharma, and launch a major new market for computational protein design.